Medical cannabis is becoming increasingly liberalised across Europe, especially in high-income western countries such as Germany, the Netherlands, Italy and Switzerland.
One of the first things a parent questions when their child is diagnosed with what doctors call “scoliosis” is whether or not they could have done something to prevent it.
It comes as no surprise that with our packed schedules and our crammed lives, that treating conditions such as anxiety and depression with prescription medication is a $15 billion a year worldwide industry. For some, prescription medications are a no-go either because of allergies or because they want to opt for something more natural.
This review highlights recent advances in understanding of the endocannabinoid system and indicates CNS disorders that may benefit from the therapeutic effects of cannabinoid treatment. Where applicable, reference is made to ongoing clinical trials of cannabinoids to alleviate symptoms of these disorders.
Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession as well as legalization of medical and recreational cannabis. In this context, patients and their physicians have had an increasing number of conversations about the risks and benefits of cannabis. While cannabis and cannabinoids continue to be evaluated as pharmacotherapy for medical conditions, the best evidence currently exists for the following medical conditions: chronic pain, neuropathic pain, and spasticity resulting from multiple sclerosis.